The fundamental problem in shock is "inadequate end-organ perfusion" #Nephpearls #AKIinICU #NephSky 📌 Low cardiac output (CO) ✔️ Hypovolemic ✔️ Cardiogenic ✔️ Obstructive 📌 Low systemic vascular resistance (SVR) aka Distributive: Sepsis

The Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy #Nephpearls #NephSky reachmd.com/programs/med...

B cell maturation, treatment targets, and therapies ca. 2026 from @kidneyint.bsky.social @kdigo.org #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42034308/

Fabry Disease: Current Perspectives on Diagnosis and Management Strategies ca. 2026 from @akdhjournal.bsky.social @saynanorouzi.bsky.social #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42331443/

ARISE FLUIDS: Vasopressors or Fluids in Early Septic Shock ca. 2026 from @nejm.org #Nephpearls #AKIinICU #NephSky 📌 No significant difference in days alive and out of hospital at day 90 ⚠️ Pulmonary edema: Lower in restricted fluids group (0.6% vs. 5.0%) 👉 pubmed.ncbi.nlm.nih.gov/42274006/

Guideline for Prevention, Detection, Evaluation, & Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome ca. 2026 from @americanheart.bsky.social @accintouch.bsky.social @amdiabetesassn.bsky.social @asnkidney.bsky.social #Nephpearls #Cardiorenal #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42265997/

C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms ca. 2026 @saynanorouzi.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42281853/

Mechanisms by which novel antihypertensive drug classes reduce blood pressure ca. 2025 from @natrevcardiol.nature.com #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/39920248/

Aprocitentan in Patients With CKD and Resistant Hypertension ca. 2026 #Nephpearls #NephSky ✅ Well tolerated ✅ Lowered BP (nighttime ambulatory BP) ✅ Markedly reduced urine albumin-to-creatinine ratio (UACR) in participants w/ CKD and resistant hypertension 👉 pubmed.ncbi.nlm.nih.gov/41363010/

Hemodynamic monitoring in in ICU: Capillary refill time (CRT), is quick, easily performed, and a long-standing component of the physical exam #Nephpearls #AKIinICU #NephSky 👉 pubmed.ncbi.nlm.nih.gov/30772908/ 👉 www.wolterskluwer.com/en/solutions...

FIND-CKD: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months ca. 2026 from @nejm.org #Nephpearls #ERA26 #NephSky 👉 www.nejm.org/doi/full/10....

Hyperkalemia and Its Treatment: Real-World Evidence and Managed Care Considerations Supporting Use of Potassium Binders ca. 2026 from @beaverspharmd.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42213908/

Consensus Recommendation: Real World Insights on Attitudes and Treatment of Hyperkalemia ca. 2026 from @garysinger.bsky.social @renalphysicians.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42069178/

Treatment of chronic hyponatremia from Dr Ewout Hoorn #Nephpearls #ERA26 #NephSky

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial ca. 2026 from @asnpublications.bsky.social #Nephpearls #ERA26 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/40913594/

Ultrafiltration and Sodium Removal in Steady Concentration Peritoneal Dialysis: A Prospective, Multicenter, Randomized, Crossover Study ca. 2026 from @asnpublications.bsky.social @wilkiemart.bsky.social #Nephpearls #ERA26 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42240452/

C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms ca. 2026 @saynanorouzi.bsky.social #Nephpearls #NephSky 👉 www.wjgnet.com/2220-3230/fu...

SAVE THE DATE for upcoming #ECNeph "Nephrotic syndrome in a patient with diabetes" 🗓️ 28th May, Thursday ⏰ 8PM IST 🇮🇳, 1030AM EST 🇺🇸, 1030PM PHT 🇵🇭 #Nephpearls #NerphSky

Glomerular frontiers: consensus perspectives from @glomcon.org @n0r0zha.bsky.social @poyanmehr.org @bettercallseeth.bsky.social @saynanorouzi.bsky.social #GlomconHawaii 🌊 2025 #NephSky #Nephpearls 👉 link.springer.com/article/10.1...

Inpatient Hypertension ? #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/38804130/ 🔳 Was the BP measured properly and accurately? 🔳 Is there evidence of acute end-organ damage? 🔳 What potential factors are contributing to the elevated BP?

Kidney disease (CKD) and heart failure (HFrEF, HFpEF): recent advances and current challenges: conclusions from @kdigo.org Controversies Conference ca. 2026 #Nephpearls #Cardiorenal #NephSky 👉 pubmed.ncbi.nlm.nih.gov/41791738/

Hypophosphatemia During Kidney Replacement Therapy and Ventilator-Free Days: A Post-Hoc Analysis of the STARRT-AKI Trial ca. 2026 @ajkd.bsky.social #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/41763519/

Hypomagnesemia and Hypermagnesemia: Treatment algorithms from @kidneyboy.bsky.social #Nephpearls #NephSky 👉 shop.lww.com/Manual-of-Ne...

Hypophosphatemia and Hyperphosphatemia: Diagnostic work up from @doctorgates.bsky.social #Nephpearls #NephSky 👉 shop.lww.com/Manual-of-Ne...

Out of Office Blood Pressure (BP) monitoring #Nephpearls #HTNSecrets #WorldHypertensionDay #WorldHypertensionDay2026 #NephSky 👉🏼 shop.elsevier.com/books/hypert...

Blood Pressure (BP) Management in the Patient with CKD ca. 2022 from @asnkidney.bsky.social #Nephpearls #WorldHypertensionDay #WorldHypertensionDay2026 👉🏼 pubmed.ncbi.nlm.nih.gov/34987024/

That's a NO ❌ to Beta Blockers in #Hepatorenal syndrome #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/24076364/

Check out the most read articles from Peritoneal Dialysis International journal #Nephpearls #NephSky 👉 journals.sagepub.com/action/showM...

Kidney Translation Podcasts 🎙️from @asnkidney @asnpublications.bsky.social @asnkidney.bsky.social #Nephpearls #NephSky 👉 journals.lww.com/asnjournals/...

Affordable 💵 SGLT2 inhibitor 💊 Thanks 🙏 for this @mcuban.bsky.social @costplusdrugs.com HT @kidneyboy.bsky.social for highlighting this #NephSky

Consensus Recommendation: Real World Insights on Attitudes and Treatment of Hyperkalemia ca. 2026 from @renalphysicians.bsky.social @garysinger.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42069178/ 👉 www.theisn.org/initiatives/...

Hypertension and CKD ca. 2026 from @doctorgates.bsky.social #Nephpearls #NephSky 👉 indianjnephrol.org/current-issue/

Summary of renal adverse events noted with targeted therapies #Nephpearls #Onconephrology 🦀 #NephSecrets #NephSky 👉 shop.elsevier.com/books/nephro...

Proposed approach to the diagnosis and management of immune checkpoint inhibitor-associated AKI ca. 2022 from @natrevneph.nature.com #Nephpearls #Onconephrology 🦀 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/36168055/

MUST KNOW: Summarized kidney adverse effects from anti-cancer therapies ca. 2022 from @asnpublications.bsky.social @kdjhaveri.bsky.social @gudnephron.bsky.social @herrmannmd.bsky.social #Nephpearls #Onconephrology 🦀 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/36821617/

How it started: Did you know that the first #Nephrology journals to create Visual Abstracts were CJASN and JASN ? @asnpublications.bsky.social #VisualAbstract #NephSky

Onconephrology focuses on management of kidney disease in cancer, which manifests itself in a variety of clinical syndromes, including AKI, CKD, hypertension, proteinuria, and electrolyte disorders #Nephpearls #Onconephrology 🦀 #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/37855786/

Proposed algorithm for the application of rituximab in minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS) ca. 2020 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/32942039/

Histopathology of MPGN and C3 glomerulopathies ca. 2015 from @natrevneph.nature.com #GlomConEurope 🇪🇺🇵🇹 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/25447133/

Treatment/ outcome has improved in ANCA-associated vasculitis (AAV) but long-term risks ⚠️ remain #GlomConEurope 🇪🇺🇵🇹 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/36617233/

Histopathologic Classification of ANCA-Associated Glomerulonephritis ca. 2010 #GlomConEurope 🇪🇺🇵🇹 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/20616173/

Therapeutic targets 🎯and positioning of treatments in IgA nephropathy 🔬 #IgAN ca. 2026 #GlomConEurope 🇪🇺🇵🇹 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/41895685/

The draft of @kdigo.org Clinical Practice Guideline for AKI/ AKD is now available for public review through 🗓️ April 27, 2026 #Nephpearls #NephSky We invite you to review the draft and share comments to help inform the final guideline 👉 kdigo.org/guidelines/a...

Did you know that the “four-hit” hypothesis for IgA nephropathy #IgAN was first clearly articulated by Hitoshi Suzuki et al. in their 2011 J. Am. Soc. Nephrol. paper, “The pathophysiology of IgA nephropathy.” #ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/21949093/

Therapeutic targets 🎯and positioning of treatments in IgA nephropathy 🔬 #IgAN ca. 2026 from @kidneyint.bsky.social #ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/41895685/

PISCES: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis ca. 2026 from @nejm.org @asnkidney.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/41201837/ 👉 www.kidneynews.org/view/journal...

Efficacy and Safety of Atrasentan in Patients with #IgAN Receiving Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) ca. 2026 from @asnpublications.bsky.social #ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 #Nephpearls #NephSky Photo Credit: @nephroseeker.medsky.social 👉 journals.lww.com/jasn/fulltex...

I made it to #ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 ... well, kinda ... Photo Credit 👉 @hswapnil.medsky.social pubmed.ncbi.nlm.nih.gov/35155869/

Trying to catch up with #IgAN trials⁉️ Check out 👉 “IgAN: An Overview of the Clinical Trials” ca. 2025 from @kidneymed.bsky.social @haresh11.bsky.social @alexgr23.bsky.social @saynanorouzi.bsky.social #ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/41050133/

SGLT2 inhibition: Pleiotropic direct cardiac and kidney effects ⁉️ #ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/35589167/